Curated disease-level target triage powered by multi-structure recurrence analysis. Ranks targets by structural tractability evidence from the frozen v5.1 engine.
Progressive motor neuron disease with no curative treatment. Multiple genetic subtypes with distinct protein targets. Current therapies (riluzole, edaravone) provide modest benefit.
Tractability Assessment: No high-priority targets. Average triage score 0. Structural evidence for druggability is limited across the target landscape.
Triage scores are computed from the frozen v5.1 Ashebo engine output. They reflect structural tractability evidence only — not clinical success probability. Components: druggability (median engine score), recurrence (hotspot convergence across structures), confidence (badge-derived), structural coverage (number of independent structures), and region quality (hotspot region count). Disease manifests are curated, not scraped. No therapeutic claims are made.